Pharmaceutical company Novo Nordisk is exploring whether the diabetes drug semaglutide, marketed by Hollywood celebrities as Ozempic, could offer benefits beyond blood sugar control. The company has initiated testing a new oral formulation of semaglutide in clinical trials to assess its potential in preventing dementia.
Semaglutide is already approved for managing type 2 diabetes and has gained popularity for its weight loss effects. Researchers are now investigating whether the drug’s effects on reducing inflammation and improving metabolic health might also translate into cognitive benefits, particularly in preventing or delaying the onset of dementia.
The trial aims to determine if long-term use of the semaglutide pill can impact brain health in at-risk populations. While the results are still pending, this research reflects a growing interest in repurposing existing medications to address neurodegenerative diseases, which currently have limited treatment options.
If successful, the findings could expand the therapeutic uses of semaglutide, providing a new tool in the fight against dementia. However, investigators emphasize that further research will be necessary to establish safety and efficacy before any formal recommendations can be made for its use as a preventive treatment for cognitive decline.